Androgen receptor expression in breast carcinoma of Egyptian patients

Rehab Monir Samaka, Sheren Fouad Younes

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Abstract

Introduction: Breast carcinoma (BC) is a heterogeneous disease, with distinctive molecular sub-types, influencing BC patients prognosis and therapeutic options. Androgen Receptor (AR) is a steroid nuclear receptor involved in complex signaling pathways, that are thought to play a role in cell proliferation. AR expression in relation to different molecular sub-types of BC is not clearly understood. Aim: The aim of this study was to evaluate the expression of AR in BC from Egyptian patients and correlate it with the standard clinico-pathologic variables, molecular sub-type of BC and the Overall Survival (OS). Materials and Methods: This retrospective study was conducted on 81 cases of BC from egyptian patients, stained immunohistochemically with AR. Chi-Square and Kaplan meyer tests were applied to study the correlation between AR expression and clinicopathologic variables and the OS of BC patients respectively. Results: Among studied BC cases, 37.04% were immunoreactive to AR. AR immunoreactivity was significantly correlated with older age (p=0.03), post-menopausal status (p=0.001), lower grade (p=0.003), the presence of in-situ component (p= 0.014), early stage of presentation (p=0.03) and good-moderate NPI (0.009). It was also correlated with Positive ER, negative HER-2/neu, low Ki67 proliferation index and luminal A subtype. AR expression didn’t correlate with the OS in the studied cases. Conclusion: AR was found to be related to favourable prognostic factors in BC but not to OS. It was particularly expressed in luminal A group and in significant proportion in Triple Negative Breast Carcinoma (TNBC), providing an opportunity for AR targeted therapy.

Original languageEnglish
Pages (from-to)EC17-EC21
JournalJournal of Clinical and Diagnostic Research
Volume10
Issue number11
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

Androgen Receptors
Breast Neoplasms
Survival
Steroid Receptors
Cell proliferation
Cytoplasmic and Nuclear Receptors
Retrospective Studies
Steroids
Cell Proliferation

Keywords

  • Immunohistochemical
  • Molecular subtypes
  • Prognosis
  • Steroid receptor

Cite this

@article{af479d46d17b440393fb331715a35acf,
title = "Androgen receptor expression in breast carcinoma of Egyptian patients",
abstract = "Introduction: Breast carcinoma (BC) is a heterogeneous disease, with distinctive molecular sub-types, influencing BC patients prognosis and therapeutic options. Androgen Receptor (AR) is a steroid nuclear receptor involved in complex signaling pathways, that are thought to play a role in cell proliferation. AR expression in relation to different molecular sub-types of BC is not clearly understood. Aim: The aim of this study was to evaluate the expression of AR in BC from Egyptian patients and correlate it with the standard clinico-pathologic variables, molecular sub-type of BC and the Overall Survival (OS). Materials and Methods: This retrospective study was conducted on 81 cases of BC from egyptian patients, stained immunohistochemically with AR. Chi-Square and Kaplan meyer tests were applied to study the correlation between AR expression and clinicopathologic variables and the OS of BC patients respectively. Results: Among studied BC cases, 37.04{\%} were immunoreactive to AR. AR immunoreactivity was significantly correlated with older age (p=0.03), post-menopausal status (p=0.001), lower grade (p=0.003), the presence of in-situ component (p= 0.014), early stage of presentation (p=0.03) and good-moderate NPI (0.009). It was also correlated with Positive ER, negative HER-2/neu, low Ki67 proliferation index and luminal A subtype. AR expression didn’t correlate with the OS in the studied cases. Conclusion: AR was found to be related to favourable prognostic factors in BC but not to OS. It was particularly expressed in luminal A group and in significant proportion in Triple Negative Breast Carcinoma (TNBC), providing an opportunity for AR targeted therapy.",
keywords = "Immunohistochemical, Molecular subtypes, Prognosis, Steroid receptor",
author = "Samaka, {Rehab Monir} and Younes, {Sheren Fouad}",
year = "2016",
month = "11",
day = "1",
doi = "10.7860/JCDR/2016/23364.8919",
language = "English",
volume = "10",
pages = "EC17--EC21",
journal = "Journal of Clinical and Diagnostic Research",
issn = "2249-782X",
publisher = "JCDR Research and Publications (Pvt) Limited",
number = "11",

}

Androgen receptor expression in breast carcinoma of Egyptian patients. / Samaka, Rehab Monir; Younes, Sheren Fouad.

In: Journal of Clinical and Diagnostic Research, Vol. 10, No. 11, 01.11.2016, p. EC17-EC21.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Androgen receptor expression in breast carcinoma of Egyptian patients

AU - Samaka, Rehab Monir

AU - Younes, Sheren Fouad

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Introduction: Breast carcinoma (BC) is a heterogeneous disease, with distinctive molecular sub-types, influencing BC patients prognosis and therapeutic options. Androgen Receptor (AR) is a steroid nuclear receptor involved in complex signaling pathways, that are thought to play a role in cell proliferation. AR expression in relation to different molecular sub-types of BC is not clearly understood. Aim: The aim of this study was to evaluate the expression of AR in BC from Egyptian patients and correlate it with the standard clinico-pathologic variables, molecular sub-type of BC and the Overall Survival (OS). Materials and Methods: This retrospective study was conducted on 81 cases of BC from egyptian patients, stained immunohistochemically with AR. Chi-Square and Kaplan meyer tests were applied to study the correlation between AR expression and clinicopathologic variables and the OS of BC patients respectively. Results: Among studied BC cases, 37.04% were immunoreactive to AR. AR immunoreactivity was significantly correlated with older age (p=0.03), post-menopausal status (p=0.001), lower grade (p=0.003), the presence of in-situ component (p= 0.014), early stage of presentation (p=0.03) and good-moderate NPI (0.009). It was also correlated with Positive ER, negative HER-2/neu, low Ki67 proliferation index and luminal A subtype. AR expression didn’t correlate with the OS in the studied cases. Conclusion: AR was found to be related to favourable prognostic factors in BC but not to OS. It was particularly expressed in luminal A group and in significant proportion in Triple Negative Breast Carcinoma (TNBC), providing an opportunity for AR targeted therapy.

AB - Introduction: Breast carcinoma (BC) is a heterogeneous disease, with distinctive molecular sub-types, influencing BC patients prognosis and therapeutic options. Androgen Receptor (AR) is a steroid nuclear receptor involved in complex signaling pathways, that are thought to play a role in cell proliferation. AR expression in relation to different molecular sub-types of BC is not clearly understood. Aim: The aim of this study was to evaluate the expression of AR in BC from Egyptian patients and correlate it with the standard clinico-pathologic variables, molecular sub-type of BC and the Overall Survival (OS). Materials and Methods: This retrospective study was conducted on 81 cases of BC from egyptian patients, stained immunohistochemically with AR. Chi-Square and Kaplan meyer tests were applied to study the correlation between AR expression and clinicopathologic variables and the OS of BC patients respectively. Results: Among studied BC cases, 37.04% were immunoreactive to AR. AR immunoreactivity was significantly correlated with older age (p=0.03), post-menopausal status (p=0.001), lower grade (p=0.003), the presence of in-situ component (p= 0.014), early stage of presentation (p=0.03) and good-moderate NPI (0.009). It was also correlated with Positive ER, negative HER-2/neu, low Ki67 proliferation index and luminal A subtype. AR expression didn’t correlate with the OS in the studied cases. Conclusion: AR was found to be related to favourable prognostic factors in BC but not to OS. It was particularly expressed in luminal A group and in significant proportion in Triple Negative Breast Carcinoma (TNBC), providing an opportunity for AR targeted therapy.

KW - Immunohistochemical

KW - Molecular subtypes

KW - Prognosis

KW - Steroid receptor

UR - http://www.scopus.com/inward/record.url?scp=84994908420&partnerID=8YFLogxK

U2 - 10.7860/JCDR/2016/23364.8919

DO - 10.7860/JCDR/2016/23364.8919

M3 - Article

VL - 10

SP - EC17-EC21

JO - Journal of Clinical and Diagnostic Research

JF - Journal of Clinical and Diagnostic Research

SN - 2249-782X

IS - 11

ER -